Highlights

  • Bubs Australia (ASX:BUB) reported Q1 FY27 net Revenue of AUD 23.1 million, down 9.8% year on year.
  • The company received permanent US FDA authorisation in September 2026 for its infant formula supply.
  • US retail distribution exceeded 12,000 stores, while retail scan sales increased 46.5% from the prior corresponding quarter.
  • September-quarter operating cash outflow was AUD 6.0 million, and available Liquidity reached AUD 13.4 million.

Bubs Australia (ASX:BUB) develops and markets infant formula and early-life nutrition products in Australia and international markets. On 20 November 2026, its shares were quoted at AUD 0.071, down 4.05% for the reported session. Recent 2026 company disclosures provide the principal context for Business performance, operational priorities and the milestones that remain to be assessed.

Infant Formula and International Sales

Bubs develops and distributes infant formula products with an expanding emphasis on the United States. The company reported products available in more than 12,000 US stores across all 50 states in the September quarter. Retail scanner data indicated sales growth even as consolidated quarterly revenue declined. This distinction matters because consumer purchases, wholesale shipments and reported accounting revenue are measured at different points. September-quarter US retail scanning growth and consolidated net revenue moved in different directions.

FDA Authorisation and Commercial Rollout

In September 2026 the company announced permanent US FDA authorisation to Supply infant formula. That regulatory milestone formalised access, but does not guarantee the Volume or timing of future purchases. The October quarterly update cited 46.5% growth in US retail scan sales against the comparable quarter. Management also discussed Marketing and inventory Investment to support sales through the existing retail network. The reported USD translation impact was one of several factors affecting the September-quarter comparison.

September Quarter Revenue and Liquidity

Q1 FY27 net revenue was AUD 23.1 million compared with AUD 25.6 million a year earlier, a 9.8% decline. The company cited foreign-exchange translation effects among the influences on US-reported revenue. Operating cash outflow increased to AUD 6.0 million from AUD 4.4 million in Q1 FY26. Available liquidity was AUD 13.4 million at September-end, comprising AUD 6.4 million in cash and AUD 7.0 million in undrawn facilities. The AUD 7.0 million undrawn Debt component should not be described as cash on hand.

Inventory, Distribution and Regulatory Risks

The infant nutrition category requires product-quality compliance and careful distribution planning. Bubs described delayed re-entry into Singapore and Vietnam and inventory investment as factors affecting cash flow. A larger store footprint may require additional Working Capital before wholesale collections match consumer demand. These factors should be treated as disclosed operating explanations rather than evidence of product-safety misconduct. The October update expressly noted a foreign-exchange translation effect on USA net revenue rather than describing all declines as reduced demand.

What to Watch Next

The next Quarterly Report can show whether retail sell-through increasingly converts into distributor orders and cash receipts. Investors can also monitor the timing of activity in Singapore and Vietnam. US market spending and inventory management remain important to liquidity following the September cash outflow. Management updates will clarify how the permanent FDA authorisation influences ongoing commercial execution. An expanded US store footprint will require continued coordination of inventory, retail promotions and wholesale replenishment.

Key Insights

Permanent US authorisation and broader retail availability coincided with lower quarterly revenue and a larger cash outflow. Sell-through, wholesale ordering and liquidity are key separate measures.